AOD-9604 in Stampriet — Fat Loss Peptide Research Guide
AOD-9604 research guide for Stampriet. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
Research-Grade AOD-9604 for Stampriet Investigators
Unlike general health products stocked in every health store, AOD-9604 moves through a global research peptide market that Stampriet residents navigate through international suppliers. What this means for Stampriet researchers is that geography is secondary to your ability to assess COA data — and those quality checks are within reach of all serious researchers. What consistently distinguishes top AOD-9604 vendors is full COA coverage: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for safety documentation. This guide walks Stampriet researchers through that evaluation process and explains what quality documentation for AOD-9604 should look like.
AOD-9604: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Stampriet comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Buying AOD-9604: Quality Markers to Look For
The first step for any Stampriet researcher sourcing AOD-9604 is locating suppliers that experienced researchers actively recommend — organic rankings are no guide to actual AOD-9604 quality. When reviewing a AOD-9604 COA, verify: the batch number corresponds to your vial, HPLC purity is ≥98%, mass spec identifies the correct molecular weight, and endotoxin levels are below the threshold for research use. For Stampriet researchers evaluating unfamiliar vendors: a test quantity before committing to research volumes before committing to research quantities is the accepted approach among experienced researchers. Keep lyophilised AOD-9604 at minus 20 degrees Celsius until ready to use; reconstitute only the quantity required for your immediate research and return unused portion to the freezer.
Order AOD-9604 — ships to Stampriet
COA-verified · International tracking · Research grade
AOD-9604 operates beyond the scope of approved drug regulation — researchers should understand that the safety data available for AOD-9604 is based on research literature rather than clinical trials. Lyophilised AOD-9604 should be stored frozen (−20°C) immediately upon receipt; avoid repeatedly thawing and refreezing reconstituted peptide by preparing small aliquots before storage. Endotoxin testing in the AOD-9604 COA is absolutely required — gram-negative bacterial endotoxins can trigger dangerous immune responses at minute levels, and no pricing advantage justifies skipping this verification. For any individual considering AOD-9604 outside a formal research context: consult a qualified physician — this compound is unapproved for human therapeutic application and its known risks are not comparable to approved pharmaceuticals.
Frequently Asked Questions
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
